Stem cells: The present, and the promise.

1. Stem cells: The present, and the promise. Professor of Biochemistry and Molecular Biology Director, The Catherine Birch McCormick Genomics Center Tim McCaffrey, Ph.D.

2. Potential uses for stem cells Aging? Diabetes? Skin?

3. Making embryonic stem cells

4. Sources of stem cells

5. Nonmalignant Diseases * Fanconi anemia * Aplastic anemia * Refractory anemia * Thalassemia * Sickle cell anemia * Amegakaryocytic thrombocytopenia * Kostmann syndrome * Blackfan-Diamond syndrome * Severe combined immunodeficiency * X-linked lymphoproliferative disorder * Wiskott-Aldrich syndrome * Hurler syndrome * Hunter syndrome * Gunther disease * Osteopetrosis * Globoid cell leukodystrophy * Adrenoleukodystrophy * Lesch-Nyhan syndrome Uses for cord blood Malignant Diseases * Acute lymphocytic leukemia * Acute myelocytic leukemia * Juvenile chronic myelogenous leukemia * Chronic myelogenous leukemia * Neuroblastoma * Refractory anemia with blasts

6. Marrow repopulation w/ stem cells

7. United States. 1997. Causes of Death.

8. Age and Cardiovascular Disease • Source: World Health Organization Autopsy Study, 1976.

9. Efficacy of Angioplasty for Dilating Blockage Textbook of Medicine, 2nd edition.

10. Surviving Myocardial Infarction Half of all myocardial infarctions are fatal. However, if ER care is available, mortality is less than 12%. Because of 1) angioplasty and 2) thrombolytics (tPA, streptokinase) clot-busters 3) aspirin 4) aggressive and new anticoagulants More people are surviving MI.

11. MI and cardiomyocyte damage

12. Strategies for cardiac repair • Simple cardiomyoplasty - - reduce the dilation surgically • Angiogenic therapy - - induce new blood muscle formation • Laser-based reperfusion -- PMR/TMR • Cardiac regeneration --- IDEAL • Cardiac stem cell therapy --- the next best thing

13. Stem cell therapy- Goals • Restore blood flood to the ischemic region --> angiogenesis alone is not enough • Replace or regenerate fused and coupledcardiomyocytes • Prevent inflammatory process • Prevent fibroproliferative stiffening • Increase cardiac performance, thus, quality of life • Survival, survival, survival

14. Types of stem cells tested • Embryonic stem cells • -cardiomyocyte progenitors (beating) • Adult stem cells • - skeletal muscle progenitors, satellite cells • hematopoetic stem cells (bone marrow derived) • mobilized hematopoetic stem cells (endogenous) • liver stem cells • mesenchymal stem cells

15. Embryoid body cardiomyocytes As few as several hundred embryonic stem cells will spontaneously aggregate. Within hours they will polarize and spontaneously contracting heart ‘beats’ are visible.

16. Problems with ES therapy • ethical issues of destroying human embryos • legal limitations prevent Federal funds to create new lines • probability of immune rejection is high • • almost no ability to control their differentiation completely • • possibility of teratocarcinoma is very real • viral and bacterial contamination of long-lived cultures • (particularly with mouse feeder layer, bovine serum) • • proven genetic deterioration of the cells • • if you can’t sell Vioxx, how do you ‘sell’ cells?

17. Adult stem cells Advantages: - almost certainly no rejection issues - no destruction of embryonic/fetal tissues - should be plentiful and renewable - might allow identification of myogenic factor Disadvantages: - currently, yield is low, so ‘mobilization’ is used - possible introduction of neo-antigens - controlling differentiation is now minimal - ??? Telomeric barriers ??? - market uncertainty “Where’s the drug?”

18. Biosense/NOGA (Cordis) GPS for the heart • Catheter tip is both an ECG electrode and a GPS antenae • Tip placement is controled by user under direction of computer mapping routine. • As new data points are gathered, the computer constructs a map from interpolation.

19. Voltage Map of the Left Ventricle 25 mV Biosense can combine electrical activity with wall motion at each point. 5 mV 1.0 cm

20. NOGA-based delivery of stem cells

21. Satellite cell cardiomyoplasty (Blue nuclei = host heart; Red = donor skeletal satellite cells)

22. SPECT and NOGA Before After Reversible 2 months post-op 15 injections of auto. bone marrow monocytes Irreversible Injection Sites

23. Questions for stem cell therapy • Is the damaging factor (virus, autoimmunity) gone? • What is the right replacement cell (s)? • What is right timing for transplantation? • How to keep the cells at the infarct site? • Will healthy cells prevent disease progression? • Will healthy myocytes couple and entrain? • BIG QUESTION: Where are the cells? • BIGGER QUESTION: Will it work in old people?

24. Real-time imaging of fluorescently tagged cells MetaMouse: epifluorescent cell detection

26. New Options for Producing Embryonic Stem Cells • Non-destructive sampling of blastocysts. • Identify non-viable blastocysts for ES production. • “Retrodifferentiation” of adult cells to stem cells.

27. Blastomere-derived ES cells. Production of ES lines without destroying embryos. From Klimanskaya, Lanza (Advanced Cell Technologies) Nature. 2006 Jan 12;439(7073):216-9.

28. Full differentiation of blast-ES Blast ES implanted into kidney capsule of immunodeficient mouse. Neural (ectodermal) Smooth muscle (mesodermal) Intestinal (endodermal) From Klimanskaya, Lanza (Advanced Cell Technologies) Nature. 2006 Jan 12;439(7073):216-9.

29. ES cells from stalled fertilizations Of 13 embryos naturally arrested at 6-7 post-fertilization, 1 embryonic stem cell line could be established.

30. Summary: • Both embryonic and adult stem cells have limitless scientific potential. • Adult stem cells probably have greater immediate therapeutic value. • Embryonic stem cells probably can be created without destroying viable embryos. • Therapeutically, probably stem-cell derived factors will be used to promote tissue regeneration from resident stem cells.